These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23640778)

  • 1. Longitudinal monitoring of cardiac siderosis using cardiovascular magnetic resonance T2* in patients with thalassemia major on various chelation regimens: a 6-year study.
    Ambati SR; Randolph RE; Mennitt K; Kleinert DA; Weinsaft JW; Giardina PJ
    Am J Hematol; 2013 Aug; 88(8):652-6. PubMed ID: 23640778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Importance of Cardiac T2* Magnetic Resonance Imaging for Monitoring Cardiac Siderosis in Thalassemia Major Patients.
    Chaosuwannakit N; Makarawate P; Wanitpongpun C
    Tomography; 2021 Apr; 7(2):130-138. PubMed ID: 33919601
    [No Abstract]   [Full Text] [Related]  

  • 3. Low prevalence of cardiac siderosis in heavily iron loaded Egyptian thalassemia major patients.
    El Beshlawy A; El Tagui M; Hamdy M; El Ghamrawy M; Azim KA; Salem D; Said F; Samir A; St Pierre T; Pennell DJ
    Ann Hematol; 2014 Mar; 93(3):375-9. PubMed ID: 23949317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Pibiri M; Nair SV; Walker JM; Pennell DJ
    J Cardiovasc Magn Reson; 2008 Feb; 10(1):12. PubMed ID: 18298856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron concentrations assessed with T2* magnetic resonance imaging in patients with beta-thalassemia major.
    Perifanis V; Christoforidis A; Vlachaki E; Tsatra I; Spanos G; Athanassiou-Metaxa M
    Int J Hematol; 2007 Dec; 86(5):385-9. PubMed ID: 18192103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
    Cassinerio E; Roghi A; Pedrotti P; Brevi F; Zanaboni L; Graziadei G; Pattoneri P; Milazzo A; Cappellini MD
    Ann Hematol; 2012 Sep; 91(9):1443-9. PubMed ID: 22572843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major.
    Alpendurada F; Smith GC; Carpenter JP; Nair SV; Tanner MA; Banya W; Dessi C; Galanello R; Walker JM; Pennell DJ
    J Cardiovasc Magn Reson; 2012 Jan; 14(1):8. PubMed ID: 22277065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac T2* MRI assessment in patients with thalassaemia major and its effect on the preference of chelation therapy.
    Akcay A; Salcioglu Z; Oztarhan K; Tugcu D; Aydogan G; Ayaz NA; Bornaun H; Sen HS; Akici F; Akdana B
    Int J Hematol; 2014 Jun; 99(6):706-13. PubMed ID: 24719246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major.
    Pathare A; Taher A; Daar S
    Ann Hematol; 2010 Apr; 89(4):405-9. PubMed ID: 19798501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiparametric Cardiac Magnetic Resonance Survey in Children With Thalassemia Major: A Multicenter Study.
    Casale M; Meloni A; Filosa A; Cuccia L; Caruso V; Palazzi G; Gamberini MR; Pitrolo L; Putti MC; D'Ascola DG; Casini T; Quarta A; Maggio A; Neri MG; Positano V; Salvatori C; Toia P; Valeri G; Midiri M; Pepe A
    Circ Cardiovasc Imaging; 2015 Aug; 8(8):e003230. PubMed ID: 26253625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between the myocardial T2* value and left ventricular volumetric and functional parameters in thalassemia major patients.
    Bayraktaroğlu S; Aydinok Y; Yildiz D; Uluer H; Savaş R; Alper H
    Diagn Interv Radiol; 2011 Dec; 17(4):346-51. PubMed ID: 21647857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.
    Vlachaki E; Agapidou A; Spanos G; Klonizakis P; Vetsiou E; Mavroudi M; Boura P
    Hemoglobin; 2015; 39(5):299-304. PubMed ID: 26177199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure.
    Pennell DJ; Carpenter JP; Roughton M; Cabantchik Z
    J Cardiovasc Magn Reson; 2011 Sep; 13(1):45. PubMed ID: 21910880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationships between pancreatic T2* values and pancreatic iron loading with cardiac dysfunctions,  hepatic and cardiac iron siderosis among Egyptian children and young adults with β-thalassaemia major and sickle cell disease: a cross-sectional study.
    Salama K; Abdelsalam A; Eldin HS; Youness E; Selim Y; Salama C; Hassanein G; Samir M; Zekri H
    F1000Res; 2020; 9():1108. PubMed ID: 34249348
    [No Abstract]   [Full Text] [Related]  

  • 15. Intermediate-term evaluation of a pratical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac t2*.
    Ha SY; Mok AS; Chu WC; Rasalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
    Hemoglobin; 2011; 35(3):199-205. PubMed ID: 21599432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major.
    Kirk P; Roughton M; Porter JB; Walker JM; Tanner MA; Patel J; Wu D; Taylor J; Westwood MA; Anderson LJ; Pennell DJ
    Circulation; 2009 Nov; 120(20):1961-8. PubMed ID: 19801505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac T2* MR in patients with thalassemia major: a 10-year long-term follow-up.
    Daar S; Al Khabori M; Al Rahbi S; Hassan M; El Tigani A; Pennell DJ
    Ann Hematol; 2020 Sep; 99(9):2009-2017. PubMed ID: 32556452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI guided iron assessment and oral chelator use improve iron status in thalassemia major patients.
    Nichols-Vinueza DX; White MT; Powell AJ; Banka P; Neufeld EJ
    Am J Hematol; 2014 Jul; 89(7):684-8. PubMed ID: 24652616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How early can myocardial iron overload occur in beta thalassemia major?
    Yang G; Liu R; Peng P; Long L; Zhang X; Yang W; Tan S; Pan H; Long X; He T; Anderson L; Lai Y
    PLoS One; 2014; 9(1):e85379. PubMed ID: 24465548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients.
    Cassinerio E; Roghi A; Orofino N; Pedrotti P; Zanaboni L; Poggiali E; Giuditta M; Consonni D; Cappellini MD
    Ann Hematol; 2015 Jun; 94(6):939-45. PubMed ID: 25563596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.